Parkinson Disease — Self-motion Perception in Parkinson's Disease
Citation(s)
Almeida QJ, Lebold CA Freezing of gait in Parkinson's disease: a perceptual cause for a motor impairment? J Neurol Neurosurg Psychiatry. 2010 May;81(5):513-8. doi: 10.1136/jnnp.2008.160580. Epub 2009 Sep 15.
Bodis-Wollner I, Yahr MD Measurements of visual evoked potentials in Parkinson's disease. Brain. 1978 Dec;101(4):661-71.
Carandini M, Churchland AK Probing perceptual decisions in rodents. Nat Neurosci. 2013 Jul;16(7):824-31. doi: 10.1038/nn.3410. Epub 2013 Jun 25. Review.
Clark JP, Adams SG, Dykstra AD, Moodie S, Jog M Loudness perception and speech intensity control in Parkinson's disease. J Commun Disord. 2014 Sep-Oct;51:1-12. doi: 10.1016/j.jcomdis.2014.08.001. Epub 2014 Aug 23.
Davidsdottir S, Wagenaar R, Young D, Cronin-Golomb A Impact of optic flow perception and egocentric coordinates on veering in Parkinson's disease. Brain. 2008 Nov;131(Pt 11):2882-93. doi: 10.1093/brain/awn237. Epub 2008 Oct 28.
Fetsch CR, Turner AH, DeAngelis GC, Angelaki DE Dynamic reweighting of visual and vestibular cues during self-motion perception. J Neurosci. 2009 Dec 9;29(49):15601-12. doi: 10.1523/JNEUROSCI.2574-09.2009.
Gu Y, Angelaki DE, Deangelis GC Neural correlates of multisensory cue integration in macaque MSTd. Nat Neurosci. 2008 Oct;11(10):1201-10. doi: 10.1038/nn.2191. Epub 2008 Sep 7.
Gullett JM, Price CC, Nguyen P, Okun MS, Bauer RM, Bowers D Reliability of three Benton Judgment of Line Orientation short forms in idiopathic Parkinson's disease. Clin Neuropsychol. 2013;27(7):1167-78. doi: 10.1080/13854046.2013.827744. Epub 2013 Aug 19.
Montse A, Pere V, Carme J, Francesc V, Eduardo T Visuospatial deficits in Parkinson's disease assessed by judgment of line orientation test: error analyses and practice effects. J Clin Exp Neuropsychol. 2001 Oct;23(5):592-8.
Morgan ML, Deangelis GC, Angelaki DE Multisensory integration in macaque visual cortex depends on cue reliability. Neuron. 2008 Aug 28;59(4):662-73. doi: 10.1016/j.neuron.2008.06.024.
Stein BE, Stanford TR Multisensory integration: current issues from the perspective of the single neuron. Nat Rev Neurosci. 2008 Apr;9(4):255-66. doi: 10.1038/nrn2331. Review. Erratum in: Nat Rev Neurosci.2008 May;9(5):406.
van der Hoorn A, Renken RJ, Leenders KL, de Jong BM Parkinson-related changes of activation in visuomotor brain regions during perceived forward self-motion. PLoS One. 2014 Apr 22;9(4):e95861. doi: 10.1371/journal.pone.0095861. eCollection 2014.
Zaidel A, Goin-Kochel RP, Angelaki DE Self-motion perception in autism is compromised by visual noise but integrated optimally across multiple senses. Proc Natl Acad Sci U S A. 2015 May 19;112(20):6461-6. doi: 10.1073/pnas.1506582112. Epub 2015 May 4.
Zaidel A, Spivak A, Grieb B, Bergman H, Israel Z Subthalamic span of beta oscillations predicts deep brain stimulation efficacy for patients with Parkinson's disease. Brain. 2010 Jul;133(Pt 7):2007-21. doi: 10.1093/brain/awq144. Epub 2010 Jun 9.
Optic Flow and Vestibular Sensory Integration in Self-motion Perception in Parkinson's Disease
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.